Liposomal NMN Platinum by Codeage

This is for adults curious about raising NAD+ (the coenzyme that powers cellular energy reactions) without megadosing niacin. It fits people in their 30s–60s noticing flagging daytime energy or recovery and those tracking metabolic labs like fasting glucose, HbA1c, and triglycerides. If you already have robust energy and excellent sleep, effects are subtler. For established B12 deficiency, correct your Vitamin B12 first; the 250 mcg here is maintenance-level, not repletion.

NMN (nicotinamide mononucleotide) is a direct precursor your cells convert to NAD+, supporting mitochondrial ATP production and enzymes involved in DNA repair (PARPs) and cellular housekeeping (sirtuins, proteins that regulate repair and metabolism). Trans-resveratrol nudges sirtuin activity, while quercetin helps with cellular stress signaling and has modest effects on hs-CRP (a systemic inflammation marker) in some responders. Betaine (trimethylglycine) donates methyl groups, buffering the nicotinamide byproduct so methylation, the body’s chemical on/off switch for genes and detox, isn’t overtaxed.

Take the three-capsule serving in the morning with food; resveratrol and quercetin absorb better with a meal, and early dosing avoids occasional sleep disruption from B12 or increased alertness. New users can start with one capsule for a week, then step up. Subjective energy changes often show within 1–2 weeks; metabolic shifts on labs such as fasting glucose or hs-CRP are better assessed after 8–12 weeks. Stay hydrated, especially if you’re caffeine-forward.

Quercetin can interact with common drugs by affecting drug-transport proteins and liver enzymes; use caution with cyclosporine, tacrolimus, calcium channel blockers, and many statins—separate by several hours and ask your clinician. Resveratrol and quercetin have mild antiplatelet effects, so avoid stacking with blood thinners like warfarin, apixaban, or high-dose fish oil before procedures. Pregnancy and breastfeeding: skip due to limited safety data. Active cancer care or complex liver disease warrants clinician guidance first. Regulatory status for NMN is evolving in the U.S.